Drugs / IFN-gamma-secreting HAdV antigen specific T cells
IFN-gamma-secreting HAdV antigen specific T cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT03378102 | Jan 2019 → Dec 2028 expected | disease related to hematopoietic stem cell transplant | Mari Dallas | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IFN-gamma-secreting HAdV antigen specific T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03378102 ↗ |
| Modality | Cell therapy | “cell-based immunotherapy” NCT03378102 ↗ |